Alto Neuroscience is down -3.8%, or -54c to $13.62.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO:
- Four new option listings and one option delisting on September 18th
- Alto Neuroscience: No demonstrative efficacy in MDD patients with vortioxetine
- Wedbush bullish on Alto Neuroscience, initiates with an Outperform
- Alto Neuroscience initiated with an Outperform at Wedbush
- Alto Neuroscience management to meet virtually with Jefferies